Jump to content
Medicinal CJC-1295

A dark-console reading of the CJC-1295 literature, traced down to the molecule: the four DPP-IV substitutions, the DAC albumin handle, and the GHRH-receptor signaling that turns a single dose into a multi-day GH/IGF-1 readout.

SOURCES · 07 / PAPERS AND REVIEWS

Where can you find the CJC-1295 studies?

The first team wanted a longer growth-hormone effect. These links open papers about people, animals, safety, and later reviews.

See the study resultsCheck common questions

How do you check a CJC-1295 claim?

The main CJC-1295 findings in people come from two papers: Teichman 2006 and Ionescu and Frohman 2006. Jette 2005 explains the albumin bond in rats. Alba 2006 reports growth in mice that lacked the body's usual growth-hormone message. Other papers explain how CJC-1295 meets cells, how labs found it in blood, and what later reviews concluded.

A finding in people can tell you more about human health than one in mice, rats, or cells in a dish. Small numbers in brackets on other pages point to the matching papers below.

Each paper below has a link you can open, plus a letter-and-number search code. Enter that code in PubMed, a free online library of medical papers, to find the exact item. A chemical formula counts the atoms in a drug, and some lists disagree on that count for the long form. The papers still agree that the long form binds albumin. This formula dispute alone cannot tell you what is inside a vial or whether its label is right.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. ↗
  8. Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs. (GHRH-sensitive adenylate cyclase characterization). 1989. PMID 2562826. ↗
  9. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency. (D-Ala2 GHRH analog study). 1994. PMID 7962295. ↗
  10. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009. PMID 19231263. ↗
  11. Modified GRF (1-29) — chemical and pharmacological description. Encyclopedic reference (no-DAC tetrasubstituted GHRH(1-29) vs CJC-1295 DAC). ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. PMID 39934495. ↗
  14. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. PMID 41966639. ↗
  15. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to clinical practice. J Clin Med. 2024;13(20):6079. ↗
  16. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  17. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  18. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  19. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  20. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  21. Reference summary. Modified GRF (1-29) - chemical and pharmacological description. Encyclopedic reference. 2024. ↗
  22. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗